DelveInsight’s Sarcopenia Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Sarcopenia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The key players of the Sarcopenia market report involved are Biophytis, Novartis, and many others
Sarcopenia is a condition that is characterized by loss of muscle mass, muscle strength, and functional muscle impairment with aging. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.
Request free sample copy- https://www.delveinsight.com/sample-request/sarcopenia-market
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Sarcopenia Market: Drugs
- And many others
Sarcopenia Market: Etiology
The etiology of sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distribution), reduced anabolic hormone levels, muscle disuse, and inflammation, driven by environmental, genetic, and behavioral factors.
Sarcopenia Market: Report
Trials with various agents, including selective androgen receptor modulators and myostatin inhibitors, show promise as future treatment options. To date, methodological challenges and controversies regarding how best to define the condition, in addition to uncertainty about what outcome measures to consider, have delayed research into possible therapeutic options. To achieve that, increased awareness of sarcopenia is of great importance to begin reaching a consensus on diagnosis and to contribute to finding a cure for this condition.
Sarcopenia Market: Insights
Current definitions of sarcopenia are only newly developed and still not entirely accepted. Reported prevalence rates of sarcopenia vary significantly due to differing definitions, tools of diagnosis, and patient populations. Estimates range from 10% in individuals >65 years of age, rising to 30% in men over 80.
Sarcopenia Market: Treatment
Early recognition and intervention are the keys to improved outcomes in patients with sarcopenia. Screening patients for impairment in their physical function and activities of daily living (ADLs) should be a routine part of healthcare visits for the elderly.
Table of content
1 Key Insight
2 Executive Summary of Sarcopenia
3 SWOT Analysis for Sarcopenia
4 Sarcopenia Market Overview at a Glance
5 Disease Background and Overview
6 Epidemiology and Patient Population
7 Country-wise Epidemiology of Sarcopenia
8 Treatment and Management
9 Unmet Needs
10 Emerging Therapies
11 Other Promising Therapies
12 Discontinued Therapies
13 Sarcopenia: 7 Major Market Analysis
14 Market Drivers
15 Market Barriers
17 DelveInsight Capabilities
19 About DelveInsight
Sarcopenia Market: Drivers
- Better insights into disease intervention
- Increase in research initiatives
- Need for a cost-effective therapy
Sarcopenia Market: Barriers
- Need for screening tools
- Implementation of Interventions
- Diagnosis associated shortcomings
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States